Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Lane

Showing results (171-180 of 235) with videos related to

Pageof 24
Sort By:
International Journal of Cancer|November 15, 2002
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)Steven J McClue, David Blake, Rosemary Clarke, et al.
Scientific Reports|July 11, 2015
Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift AssaysBan Xiong Tan, Christopher J Brown, Fernando J Ferrer, et al.
Journal of Biomolecular Screening|January 31, 2014
The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4Larisa Yurlova, Maarten Derks, Andrea Buchfellner, et al.
Cell Reports|August 11, 2021
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision MedicineLe-Ann Hwang, Beng Hooi Phang, Oi Wah Liew, et al.
International Journal of Cancer|November 13, 2008
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft modelMaria Virginia C L Appleyard, Mary A O'Neill, Karen E Murray, et al.
EMBO Reports|June 2, 2012
Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasionCynthia R Coffill, Patricia A J Muller, Hue Kian Oh, et al.
Cell Chemical Biology|July 15, 2021
CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicityYing Yu Liang, Smaranda Bacanu, Lekshmy Sreekumar, et al.
Breast Cancer Research : BCR|January 22, 2011
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patientsJean-Christophe Bourdon, Marie P Khoury, Alexandra Diot, et al.
Journal of Molecular Biology|March 29, 2008
Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcriptionMeera Gurumurthy, Chuan Hao Tan, Raymond Ng, et al.
Cell Chemical Biology|January 24, 2018
Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate DehydrogenaseJoana Costeira-Paulo, Joseph Gault, Gergana Popova, et al.
Pageof 24

Showing results (171-180 of 235) with videos related to

Sort By:
Pageof 24
International Journal of Cancer|November 15, 2002
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)Steven J McClue, David Blake, Rosemary Clarke, et al.
Scientific Reports|July 11, 2015
Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift AssaysBan Xiong Tan, Christopher J Brown, Fernando J Ferrer, et al.
Journal of Biomolecular Screening|January 31, 2014
The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4Larisa Yurlova, Maarten Derks, Andrea Buchfellner, et al.
Cell Reports|August 11, 2021
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision MedicineLe-Ann Hwang, Beng Hooi Phang, Oi Wah Liew, et al.
International Journal of Cancer|November 13, 2008
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft modelMaria Virginia C L Appleyard, Mary A O'Neill, Karen E Murray, et al.
EMBO Reports|June 2, 2012
Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasionCynthia R Coffill, Patricia A J Muller, Hue Kian Oh, et al.
Cell Chemical Biology|July 15, 2021
CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicityYing Yu Liang, Smaranda Bacanu, Lekshmy Sreekumar, et al.
Breast Cancer Research : BCR|January 22, 2011
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patientsJean-Christophe Bourdon, Marie P Khoury, Alexandra Diot, et al.
Journal of Molecular Biology|March 29, 2008
Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcriptionMeera Gurumurthy, Chuan Hao Tan, Raymond Ng, et al.
Cell Chemical Biology|January 24, 2018
Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate DehydrogenaseJoana Costeira-Paulo, Joseph Gault, Gergana Popova, et al.
Pageof 24